Kenji Nakatsuma1, Hiroki Shiomi2, Takeshi Morimoto3, Hirotoshi Watanabe2, Yoshihisa Nakagawa4, Yutaka Furukawa5, Kazushige Kadota6, Kenji Ando7, Koh Ono2, Satoshi Shizuta2, Takeshi Kimura2. 1. Department of Cardiology, Mitsubishi Kyoto Hospital, 1 Gosho-cho, Nishikyo-ku, Kyoto, Japan. 2. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan. 3. Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan. 4. Division of Cardiology, Tenri Hospital, 200 Mishima-cho, Tenri, Nara, Japan. 5. Division of Cardiology, Kobe City Medical Center General Hospital, 1-1, 2 Minatoshimaminami-cho, Chuou-ku, Kobe, Hyogo, Japan. 6. Division of Cardiology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, Japan. 7. Division of Cardiology, Kokura Memorial Hospital, 2-1, 3 Asano, Kokurakita-ku, Kitakyushu, Fukuoka, Japan.
Abstract
Aims: To evaluate the influence of a history of cancer on clinical outcomes in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Methods and results: In the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/coronary artery bypass grafting (CABG) Registry Cohort-2, there were 12 180 CAD patients who received PCI with stents. There were 1109 patients with a history of cancer (cancer group) and 11 071 patients without cancer (non-cancer group). The cumulative 5-year incidences of cardiac death and heart failure (HF) hospitalization were significantly higher in the cancer group than in the non-cancer group (12.4% vs. 7.5%, P < 0.001 and 12.1% vs. 7.6%, P < 0.001, respectively). Even after adjusting for confounders, the excess risk of the cancer group relative to non-cancer group for cardiac death and HF hospitalization remained significant [hazard ratio (HR) 1.27, 95% confidence interval (95% CI) 1.05-1.53; P = 0.02, and HR 1.39, 95% CI 1.13-1.68; P = 0.002, respectively]. Also, the cancer group had a trend toward higher adjusted risk for definite or probable stent thrombosis as compared with the non-cancer group (HR 1.49, 95% CI 0.99-2.16; P = 0.055). The cancer group had significantly higher adjusted risk for all-cause death, non-cardiac death, major bleeding, and non-CABG surgery than the non-cancer group, while the risks for myocardial infarction and stroke were neutral between the two groups. Conclusion: Patients with a history of cancer at the time of PCI had increased risk for cardiac events such as cardiac death and HF hospitalization as well as non-cardiac events such as non-cardiac death, major bleeding, and non-CABG surgery.
Aims: To evaluate the influence of a history of cancer on clinical outcomes in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Methods and results: In the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/coronary artery bypass grafting (CABG) Registry Cohort-2, there were 12 180 CAD patients who received PCI with stents. There were 1109 patients with a history of cancer (cancer group) and 11 071 patients without cancer (non-cancer group). The cumulative 5-year incidences of cardiac death and heart failure (HF) hospitalization were significantly higher in the cancer group than in the non-cancer group (12.4% vs. 7.5%, P < 0.001 and 12.1% vs. 7.6%, P < 0.001, respectively). Even after adjusting for confounders, the excess risk of the cancer group relative to non-cancer group for cardiac death and HF hospitalization remained significant [hazard ratio (HR) 1.27, 95% confidence interval (95% CI) 1.05-1.53; P = 0.02, and HR 1.39, 95% CI 1.13-1.68; P = 0.002, respectively]. Also, the cancer group had a trend toward higher adjusted risk for definite or probable stent thrombosis as compared with the non-cancer group (HR 1.49, 95% CI 0.99-2.16; P = 0.055). The cancer group had significantly higher adjusted risk for all-cause death, non-cardiac death, major bleeding, and non-CABG surgery than the non-cancer group, while the risks for myocardial infarction and stroke were neutral between the two groups. Conclusion:Patients with a history of cancer at the time of PCI had increased risk for cardiac events such as cardiac death and HF hospitalization as well as non-cardiac events such as non-cardiac death, major bleeding, and non-CABG surgery.
Authors: Raymundo A Quintana; Dominique J Monlezun; Giovanni Davogustto; Humberto R Saenz; Francisco Lozano-Ruiz; Daisuke Sueta; Kenichi Tsujita; Uri Landes; Ali E Denktas; Mahboob Alam; David Paniagua; Daniel Addison; Hani Jneid Journal: Int J Cardiol Date: 2019-09-12 Impact factor: 4.164
Authors: Yasushi Ueki; Benjamin Vögeli; Alexios Karagiannis; Thomas Zanchin; Christian Zanchin; Daniel Rhyner; Tatsuhiko Otsuka; Fabien Praz; George C M Siontis; Christina Moro; Stefan Stortecky; Michael Billinger; Marco Valgimigli; Thomas Pilgrim; Stephan Windecker; Thomas Suter; Lorenz Räber Journal: JACC CardioOncol Date: 2019-12-17
Authors: Isabela Bispo Santos da Silva Costa; Fernanda Thereza de Almeida Andrade; Diego Carter; Vinicius B Seleme; Maycon Santos Costa; Carlos M Campos; Ludhmila Abrahão Hajjar Journal: Front Cardiovasc Med Date: 2021-06-09